Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Thatcher

Showing results (201-210 of 289) with videos related to

Pageof 29
Sort By:
European Journal of Cancer (Oxford, England : 1990)|January 1, 1995
The feasibility of using glycosylated recombinant human granulocyte colony-stimulating factor (G-CSF) to increase the planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) in the treatment of small cell lung cancer. Medical Research Council Lung Cancer Working PartyN Thatcher, H Anderson, N M Bleehen, et al.
British Journal of Diseases of the Chest|January 1, 1984
Moderate to high dose cyclophosphamide and intercalated Corynebacterium parvum in patients with metastatic lung cancerN Thatcher, D Honeybourne, J Wagstaff, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 6, 2011
1st ESMO Consensus Conference in lung cancer; Lugano 2010: small-cell lung cancerR Stahel, N Thatcher, M Früh, et al.
British Journal of Cancer|May 1, 1989
Expression of epidermal growth factor receptor (EGF-R) in non-small cell lung cancer. Use of archival tissue and correlation of EGF-R with histology, tumour size, node status and survivalH Dazzi, P S Hasleton, N Thatcher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2000
Phase II study of oral topotecan in advanced non-small cell lung cancerS C White, S Cheeseman, N Thatcher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1995
Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancerE de Campos, J Radford, W Steward, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1992
Suitability of cisplatin solutions for 14-day continuous infusion by ambulatory pumpM Hrubisko, A T Mc Gown, J A Prendiville, et al.
Cancer|November 15, 1987
Ifosfamide, etoposide, and thoracic irradiation therapy in 163 patients with unresectable small cell lung cancerN Thatcher, T Cerny, R Stout, et al.
Ciba Foundation Symposium|January 1, 1990
Growth factor-assisted chemotherapy--the Manchester experienceD Crowther, J H Scarffe, A Howell, et al.
Cancer|January 1, 1988
Double alkylating agent therapy with ifosfamide and cyclophosphamide for advanced non-small cell lung cancer. From the Manchester Lung Tumour GroupN Thatcher, D B Smith, M J Lind, et al.
Pageof 29

Showing results (201-210 of 289) with videos related to

Sort By:
Pageof 29
European Journal of Cancer (Oxford, England : 1990)|January 1, 1995
The feasibility of using glycosylated recombinant human granulocyte colony-stimulating factor (G-CSF) to increase the planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) in the treatment of small cell lung cancer. Medical Research Council Lung Cancer Working PartyN Thatcher, H Anderson, N M Bleehen, et al.
British Journal of Diseases of the Chest|January 1, 1984
Moderate to high dose cyclophosphamide and intercalated Corynebacterium parvum in patients with metastatic lung cancerN Thatcher, D Honeybourne, J Wagstaff, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 6, 2011
1st ESMO Consensus Conference in lung cancer; Lugano 2010: small-cell lung cancerR Stahel, N Thatcher, M Früh, et al.
British Journal of Cancer|May 1, 1989
Expression of epidermal growth factor receptor (EGF-R) in non-small cell lung cancer. Use of archival tissue and correlation of EGF-R with histology, tumour size, node status and survivalH Dazzi, P S Hasleton, N Thatcher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2000
Phase II study of oral topotecan in advanced non-small cell lung cancerS C White, S Cheeseman, N Thatcher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1995
Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancerE de Campos, J Radford, W Steward, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1992
Suitability of cisplatin solutions for 14-day continuous infusion by ambulatory pumpM Hrubisko, A T Mc Gown, J A Prendiville, et al.
Cancer|November 15, 1987
Ifosfamide, etoposide, and thoracic irradiation therapy in 163 patients with unresectable small cell lung cancerN Thatcher, T Cerny, R Stout, et al.
Ciba Foundation Symposium|January 1, 1990
Growth factor-assisted chemotherapy--the Manchester experienceD Crowther, J H Scarffe, A Howell, et al.
Cancer|January 1, 1988
Double alkylating agent therapy with ifosfamide and cyclophosphamide for advanced non-small cell lung cancer. From the Manchester Lung Tumour GroupN Thatcher, D B Smith, M J Lind, et al.
Pageof 29